Notably, consumers who may be experiencing digestive issues may be seeking to have more control over their food, and as a result, are eating at home instead of eating out
Prior authorization requirements are common, requiring documentation of BMI over 30 kg/m or over 27 kg/m with comorbidities, failed attempts at diet and exercise, and sometimes trial of other weight loss medications
Tirzepatide (Personalized Tirzepatide+ / Zepbound / Mounjaro) Tirzepatide is a dual GIP and GLP-1 receptor agonist - meaning it activates two hormone pathways instead of one
Network meta-analyses estimate approximately 23.77% average weight loss for retatrutide versus 16.79% for tirzepatide
If you meet the following criteria, the lawyers at Salvi, Schostok & Pritchard P.C
GLP-1 Therapies Outperform Bariatric Surgery in Cancer Risk Reduction A 2025 study published in eClinicalMedicine (Wolff Sagy Y et al.) compared cancer outcomes in patients receiving GLP-1 receptor agonists versus those who had undergone bariatric metabolic surgery